title: ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
abstract: OBJECTIVE
  Polymorphisms that are associated with ABCB1 expression and function may be linked to treatment efficacy and the development of neutropenia and neurotoxicity in patients with androgen-independent prostate cancer receiving docetaxel.
  
  
  METHODS
  Patients with androgen-independent prostate cancer treated with docetaxel alone (n = 23) or docetaxel and thalidomide (n = 50) were genotyped for the ABCB1 1236C>T, 2677 G>T/A, and 3435 C>T alleles by direct sequencing, and diplotypes were constructed using an EM algorithm. The data were then compared with duration to onset of peripheral neuropathy, neutropenia grade, and survival after docetaxel.
  
  
  RESULTS
  For patients receiving docetaxel alone, individuals carrying a diplotype consisting of the 1236C-2677G-3435C linked alleles had improved overall survival after treatment (P = 0.0017). Additionally, patients treated with docetaxel and thalidomide carrying a diplotype consisting of the 2677T-3435T haplotype had a shorter median survival (P = 0.045). After adjusting for a particular set of polymorphisms and diplotype groupings, a hazard ratio of 10.87 was found for patients carrying the 2677GG genotype versus patients carrying other genotypes (P = 0.0048) in the docetaxel and thalidomide cohort. Among both treatment arms together, individuals carrying the 2677GG genotype also had a significantly longer time to neuropathy (P = 0.035). Finally, there was a strong trend toward patients carrying the 2677TT-3435TT diplotype having higher grades of neutropenia (P = 0.053).
  
  
  CONCLUSIONS
  The data suggest that docetaxel-induced neuropathy, neutropenia grade, and overall survival could be linked to ABCB1 allelic variants with ensuing negative implications for docetaxel treatment in patients carrying ABCB1 variant genotypes.
authors.affiliation: Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
authors.forename: Tristan M
authors.initials: TM
authors.lastname: Sissung
authors.forename: Caitlin E
authors.initials: CE
authors.lastname: Baum
authors.forename: John
authors.initials: J
authors.lastname: Deeken
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.forename: Jeanny
authors.initials: J
authors.lastname: Aragon-Ching
authors.forename: Seth M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: William
authors.initials: W
authors.lastname: Dahut
authors.forename: Alex
authors.initials: A
authors.lastname: Sparreboom
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000728:Androgens / Q000378:metabolism; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D043823:Taxoids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000728:Androgens; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D013792:Thalidomide